Gene-Chemical Interaction Annotations Click to see Annotation Detail View
Term | Qualifier | Evidence | With | Reference | Notes | Source | Original Reference(s) | (+)-schisandrin B | multiple interactions | EXP | | 6480464 | schizandrin B inhibits the reaction [Carbon Tetrachloride results in increased expression of ANAPC16 mRNA] | CTD | PMID:31150632 | (1->4)-beta-D-glucan | multiple interactions | ISO | Anapc16 (Mus musculus) | 6480464 | [perfluorooctane sulfonic acid co-treated with Cellulose] results in increased expression of ANAPC16 mRNA | CTD | PMID:36331819 | 1,2-dimethylhydrazine | multiple interactions | ISO | Anapc16 (Mus musculus) | 6480464 | [1 and 2-Dimethylhydrazine co-treated with Folic Acid] results in decreased expression of ANAPC16 mRNA | CTD | PMID:22206623 | 1,2-dimethylhydrazine | affects expression | ISO | Anapc16 (Mus musculus) | 6480464 | 1 and 2-Dimethylhydrazine affects the expression of ANAPC16 mRNA | CTD | PMID:22206623 | 17alpha-ethynylestradiol | decreases expression | EXP | | 6480464 | Ethinyl Estradiol results in decreased expression of ANAPC16 mRNA | CTD | PMID:29097150 | 17beta-estradiol | decreases expression | ISO | ANAPC16 (Homo sapiens) | 6480464 | Estradiol results in decreased expression of ANAPC16 mRNA | CTD | PMID:23019147 | 2,3,7,8-tetrachlorodibenzodioxine | multiple interactions | ISO | Anapc16 (Mus musculus) | 6480464 | [TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of ANAPC16 mRNA | CTD | PMID:25975270 | 2,3,7,8-tetrachlorodibenzodioxine | increases expression | EXP | | 6480464 | Tetrachlorodibenzodioxin results in increased expression of ANAPC16 mRNA | CTD | PMID:33387578 | 2-hydroxypropanoic acid | decreases expression | ISO | ANAPC16 (Homo sapiens) | 6480464 | Lactic Acid results in decreased expression of ANAPC16 mRNA | CTD | PMID:30851411 | aflatoxin B1 | increases expression | ISO | Anapc16 (Mus musculus) | 6480464 | Aflatoxin B1 results in increased expression of ANAPC16 mRNA | CTD | PMID:19770486 | arsane | increases methylation | ISO | ANAPC16 (Homo sapiens) | 6480464 | Arsenic results in increased methylation of ANAPC16 promoter | CTD | PMID:21291286 | arsenic atom | increases methylation | ISO | ANAPC16 (Homo sapiens) | 6480464 | Arsenic results in increased methylation of ANAPC16 promoter | CTD | PMID:21291286 | benzo[a]pyrene | decreases expression | ISO | Anapc16 (Mus musculus) | 6480464 | Benzo(a)pyrene results in decreased expression of ANAPC16 mRNA | CTD | PMID:19770486 | benzo[a]pyrene | increases methylation | ISO | ANAPC16 (Homo sapiens) | 6480464 | Benzo(a)pyrene results in increased methylation of ANAPC16 5' UTR | CTD | PMID:27901495 | bisphenol A | increases expression | ISO | Anapc16 (Mus musculus) | 6480464 | bisphenol A results in increased expression of ANAPC16 mRNA | CTD | PMID:26063408 | bisphenol A | decreases methylation | ISO | ANAPC16 (Homo sapiens) | 6480464 | bisphenol A results in decreased methylation of ANAPC16 gene | CTD | PMID:31601247 | bisphenol A | multiple interactions | ISO | ANAPC16 (Homo sapiens) | 6480464 | [bisphenol A co-treated with Fulvestrant] results in increased methylation of ANAPC16 gene | CTD | PMID:31601247 | cadmium atom | multiple interactions | ISO | ANAPC16 (Homo sapiens) | 6480464 | [Cadmium Chloride results in increased abundance of Cadmium] which results in increased expression of ANAPC16 mRNA | CTD | PMID:35301059 | cadmium dichloride | multiple interactions | ISO | ANAPC16 (Homo sapiens) | 6480464 | [Cadmium Chloride results in increased abundance of Cadmium] which results in increased expression of ANAPC16 mRNA | CTD | PMID:35301059 | carbon nanotube | increases expression | ISO | Anapc16 (Mus musculus) | 6480464 | Nanotubes and Carbon results in increased expression of ANAPC16 mRNA | CTD | PMID:25554681 | chlorpyrifos | increases expression | ISO | Anapc16 (Mus musculus) | 6480464 | Chlorpyrifos results in increased expression of ANAPC16 mRNA | CTD | PMID:37019170 | copper(II) sulfate | decreases expression | ISO | ANAPC16 (Homo sapiens) | 6480464 | Copper Sulfate results in decreased expression of ANAPC16 mRNA | CTD | PMID:19549813 | cyclosporin A | increases expression | ISO | ANAPC16 (Homo sapiens) | 6480464 | Cyclosporine results in increased expression of ANAPC16 mRNA | CTD | PMID:27989131 | dibutyl phthalate | decreases expression | ISO | Anapc16 (Mus musculus) | 6480464 | Dibutyl Phthalate results in decreased expression of ANAPC16 mRNA | CTD | PMID:21266533 | dicrotophos | decreases expression | ISO | ANAPC16 (Homo sapiens) | 6480464 | dicrotophos results in decreased expression of ANAPC16 mRNA | CTD | PMID:28302478 | dioxygen | decreases expression | ISO | Anapc16 (Mus musculus) | 6480464 | Oxygen deficiency results in decreased expression of ANAPC16 mRNA | CTD | PMID:24205000 | dorsomorphin | multiple interactions | ISO | ANAPC16 (Homo sapiens) | 6480464 | [NOG protein co-treated with Valproic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1 and 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ANAPC16 mRNA | CTD | PMID:27188386 | doxorubicin | decreases expression | ISO | ANAPC16 (Homo sapiens) | 6480464 | Doxorubicin results in decreased expression of ANAPC16 mRNA | CTD | PMID:29803840 | endosulfan | increases expression | EXP | | 6480464 | Endosulfan results in increased expression of ANAPC16 mRNA | CTD | PMID:29391264 | enzyme inhibitor | multiple interactions | ISO | ANAPC16 (Homo sapiens) | 6480464 | [Enzyme Inhibitors results in decreased activity of OGA protein] which results in increased O-linked glycosylation of ANAPC16 protein | CTD | PMID:23301498 | folic acid | multiple interactions | ISO | Anapc16 (Mus musculus) | 6480464 | [1 and 2-Dimethylhydrazine co-treated with Folic Acid] results in decreased expression of ANAPC16 mRNA | CTD | PMID:22206623 | formaldehyde | increases expression | ISO | ANAPC16 (Homo sapiens) | 6480464 | Formaldehyde results in increased expression of ANAPC16 mRNA | CTD | PMID:23649840 | fulvestrant | multiple interactions | ISO | ANAPC16 (Homo sapiens) | 6480464 | [bisphenol A co-treated with Fulvestrant] results in increased methylation of ANAPC16 gene | CTD | PMID:31601247 | fulvestrant | increases methylation | ISO | ANAPC16 (Homo sapiens) | 6480464 | Fulvestrant results in increased methylation of ANAPC16 gene | CTD | PMID:31601247 | gentamycin | increases expression | EXP | | 6480464 | Gentamicins results in increased expression of ANAPC16 mRNA | CTD | PMID:33387578 | miconazole | increases expression | ISO | Anapc16 (Mus musculus) | 6480464 | Miconazole results in increased expression of ANAPC16 mRNA | CTD | PMID:27462272 | N-methyl-4-phenylpyridinium | increases expression | ISO | ANAPC16 (Homo sapiens) | 6480464 | 1-Methyl-4-phenylpyridinium results in increased expression of ANAPC16 mRNA | CTD | PMID:24810058 | paracetamol | affects expression | ISO | Anapc16 (Mus musculus) | 6480464 | Acetaminophen affects the expression of ANAPC16 mRNA | CTD | PMID:17562736 | paracetamol | increases expression | EXP | | 6480464 | Acetaminophen results in increased expression of ANAPC16 mRNA | CTD | PMID:33387578 | paracetamol | increases expression | ISO | ANAPC16 (Homo sapiens) | 6480464 | Acetaminophen results in increased expression of ANAPC16 mRNA | CTD | PMID:22230336 | perfluorooctane-1-sulfonic acid | multiple interactions | ISO | Anapc16 (Mus musculus) | 6480464 | [perfluorooctane sulfonic acid co-treated with Cellulose] results in increased expression of ANAPC16 mRNA | CTD | PMID:36331819 | pirinixic acid | increases expression | ISO | Anapc16 (Mus musculus) | 6480464 | pirinixic acid results in increased expression of ANAPC16 mRNA | CTD | PMID:18301758 | rac-lactic acid | decreases expression | ISO | ANAPC16 (Homo sapiens) | 6480464 | Lactic Acid results in decreased expression of ANAPC16 mRNA | CTD | PMID:30851411 | resveratrol | decreases expression | ISO | Anapc16 (Mus musculus) | 6480464 | resveratrol results in decreased expression of ANAPC16 protein | CTD | PMID:25505154 | SB 431542 | multiple interactions | ISO | ANAPC16 (Homo sapiens) | 6480464 | [NOG protein co-treated with Valproic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1 and 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ANAPC16 mRNA | CTD | PMID:27188386 | sunitinib | increases expression | ISO | ANAPC16 (Homo sapiens) | 6480464 | Sunitinib results in increased expression of ANAPC16 mRNA | CTD | PMID:31533062 | tetrachloromethane | increases expression | EXP | | 6480464 | Carbon Tetrachloride results in increased expression of ANAPC16 mRNA | CTD | PMID:31150632 | tetrachloromethane | increases expression | ISO | Anapc16 (Mus musculus) | 6480464 | Carbon Tetrachloride results in increased expression of ANAPC16 mRNA | CTD | PMID:31919559 | tetrachloromethane | multiple interactions | EXP | | 6480464 | schizandrin B inhibits the reaction [Carbon Tetrachloride results in increased expression of ANAPC16 mRNA] | CTD | PMID:31150632 | thioacetamide | increases expression | EXP | | 6480464 | Thioacetamide results in increased expression of ANAPC16 mRNA | CTD | PMID:34492290 | tunicamycin | increases expression | ISO | ANAPC16 (Homo sapiens) | 6480464 | Tunicamycin results in increased expression of ANAPC16 mRNA | CTD | PMID:29453283 | valproic acid | affects expression | ISO | ANAPC16 (Homo sapiens) | 6480464 | Valproic Acid affects the expression of ANAPC16 mRNA | CTD | PMID:25979313 | valproic acid | multiple interactions | ISO | ANAPC16 (Homo sapiens) | 6480464 | [NOG protein co-treated with Valproic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1 and 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ANAPC16 mRNA | CTD | PMID:27188386 | valproic acid | decreases expression | ISO | ANAPC16 (Homo sapiens) | 6480464 | Valproic Acid results in decreased expression of ANAPC16 mRNA | CTD | PMID:23179753 more ... | |